8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


       Date of report (Date of earliest event reported): January 28, 2004


                         AMERICAN BIO MEDICA CORPORATION
                  ---------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

          New York                        0-28666                14-1702188
- ------------------------------    -----------------------  -------------------
(State or Other Jurisdiction of  (Commission File Number) (IRS Employer
            Incorporation)                                Identification Number)



                      122 Smith Road, Kinderhook, NY 12106
            ---------------------------------------------------------
               (Address of Principal Executive Offices) (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243






ITEM 5.      OTHER MATTERS



         On January 28, 2004, the Registrant  appointed  Daniel W. Kollin to its
Board of Directors.  Mr.  Kollin was also  appointed to the  Registrant's  Audit
Committee.

         On January 28, 2004 the  Registrant's  Board of Directors  accepted the
resignation of Dr. Gerald W. Lynch from the Registrant's Board of Directors. Dr.
Lynch also served on the  Registrant's  Audit and Compensation  Committees.  The
Registrant is unaware of any  disagreement  Dr. Lynch has with the Registrant on
any matter relating to the Registrant's  operations,  policies or practices, nor
has Dr. Lynch provided a letter outlining any such disagreements.

         On January 30, 2004, the Registrant's Board of Directors announced the
resignation of Douglas Casterlin from the position of Executive Vice President
of Operations.

ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.

         (c)     Exhibits.

                  The following exhibits are filed with this report on Form 8-K:

                  99.1     American Bio Medica  Corporation  press release dated
                           January 30, 2004.







                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    AMERICAN BIO MEDICA CORPORATION (Registrant)


Dated:  January 30, 2004            By:      /s/ Keith E. Palmer
                                       -----------------------------------------
                                             Keith E. Palmer
                                             Chief Financial Officer






                                  Exhibit Index


Exhibit No.       Description                                   Page No.
- -----------       -----------                                   --------

     99.1         American Bio Medica Corporation press             5
                  release dated January 30. 2004.

EX-99.1

                                                                 EXHIBIT 99.1

FOR IMMEDIATE RELEASE:

            ABMC APPOINTS DANIEL W. KOLLIN TO ITS BOARD OF DIRECTORS

Kinderhook, N.Y., January 30, 2004 - American Bio Medica Corporation
(Nasdaq:ABMC) today announced the appointment of Daniel W. Kollin to its Board
of Directors, effective January 28, 2004. Kollin is a principal of BioMed
Capital Group Ltd., a firm that provides strategic and business advisory
services. He has over twenty years experience in investment banking, venture
capital and corporate management, specializing in pharmaceutical, biotechnology
and healthcare companies in North America and Europe. He had previously served
on the ABMC Board of Directors in 2003.

Kollin previously served as a Vice President of Prudential-Bache Capital Funding
and Director of Corporate Finance and partner of Whale Securities Corp. Before
his involvement in the financial services industry, Kollin held marketing,
planning and development executive positions with Becton-Dickinson and Co. and
Sandoz, Inc. He currently serves on the Board of Directors of IsoTis
Orthobiologics (TORONTO:ISO). He received his MBA from The Wharton School of the
University of Pennsylvania.

"We are pleased that Dan has agreed to re-join our Board," stated ABMC President
Edmund Jaskiewicz. "Dan's extensive experience will prove to be invaluable to
ABMC. The insight and guidance he can provide on a range of issues makes him a
strong addition to our team.
We look forward to benefiting from his expertise and experience in the future."

Kollin fills a vacancy left by Dr. Gerald W. Lynch who resigned from the ABMC
Board effective January 28, 2004.

The Company also announced that Douglas Casterlin, ABMC Executive Vice President
of Operations resigned to pursue opportunities outside of the Company.

"We would like to thank Dr. Lynch for his dedicated service to the ABMC Board
and we wish him all the best. We also would like to extend our appreciation to
Doug for his significant contributions to ABMC during his tenure with the
Company."

ABOUT AMERICAN BIO MEDICA CORPORATION

American Bio Medica Corporation is a biotechnology company that develops,
manufactures and markets accurate, cost-effective immunoassay diagnostic test
kits, including some of the world's most effective point-of-collection tests for
drugs of abuse. The Company and its worldwide distribution network target the
workplace, government, corrections, clinical and educational markets. ABMC's
Rapid Drug Screen(R), Rapid One(R), Rapid Tec(R) and Rapid Tec Cup(TM) products
test for the presence or absence of drugs of abuse in urine, while OralStat(R)
tests for the presence or absence of drugs of abuse in saliva. ABMC has been
named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the
fastest-growing technology companies in North America.

This release may contain forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results to
differ, and such differences could be material. Such risks and uncertainties
include, but are not limited to, the following: continued acceptance of the
Company's products, increased levels of competition in our industry, the
acceptance of new products, inherent risks associated with product development
and intellectual property rights, the Company's dependence on key personnel,
third party sales and suppliers. There can be no assurance that the Company will
be successful in addressing such risks and uncertainties and the Company assumes
no duty to update any forward-looking statements based upon actual results.
Investors are strongly encouraged to review the section entitled "Risk Factors"
in the Company's annual report on Form 10-KSB for the fiscal year ended December
31, 2002, and quarterly reports on Form 10-QSB on file with the Securities and
Exchange Commission for a discussion of risks and uncertainties that could
affect operating results and the market price of the Company's common shares.

                                       ###